Advanced search
Publication Cover
Future Oncology Volume 17, 2021 - Issue 30
Submit an article Journal homepage
3,046
Views
6
CrossRef citations to date
0
Altmetric
Research Article

Real-World Use and Acceptance of Biosimilar Monoclonal Antibodies of Rituximab in Oncology Practice in the USA

Ahmed Shelbaya1 Pfizer Oncology, Pfizer Inc,235 East 42nd Street, New York, NY 10017, USA;2 Department of Epidemiology, Mailman School of Public Health,Columbia University,722 West 168th Street, New York, NY 10032, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1028-5866View further author information
ORCID Icon,
John M Kelton1 Pfizer Oncology, Pfizer Inc,235 East 42nd Street, New York, NY 10017, USAView further author information
,
Jeffrey Thompson3 Health Division, Kantar,175 Greenwich Street, 35th Floor, New York, NY 10007, USAView further author information
,
Jose MJ Alvir4 Statistical Research & Data Science Center, Pfizer Inc,235 East 42nd Street, New York, NY 10017, USAView further author information
,
Martine C Maculaitis3 Health Division, Kantar,175 Greenwich Street, 35th Floor, New York, NY 10007, USAORCID Iconhttps://orcid.org/0000-0001-8388-5315View further author information
ORCID Icon &
Jingyan Yang1 Pfizer Oncology, Pfizer Inc,235 East 42nd Street, New York, NY 10017, USA;5 Institute for Social & Economic Research & Policy (ISERP),Columbia University,420 West 118th Street, Suite 370, New York, NY 10027, USAORCID Iconhttps://orcid.org/0000-0001-5523-649XView further author information
ORCID Icon
Pages 3941-3950 | Received 18 May 2021, Accepted 25 Jun 2021, Published online: 14 Jul 2021

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Patrick Cobb, Dietger Niederwieser, Stanley Cohen, Caroline Hamm, Gerd Burmester, Neungseon Seo, Sonya G Lehto & Vladimir Hanes. (2022) A Review of the Totality of Evidence in the Development of ABP 798, A Rituximab Biosimilar. Immunotherapy 14:9, pages 727-740.
Read now

Articles from other publishers (5)

Kate E. Coakley, Richard M. Bambury, Eimear McGuinness, Maeve Dennehy, Cian Ronayne, Mary Cahill & Séamus O’Reilly. (2024) An evaluation of the utilisation of biosimilar monoclonal antibody drugs in Ireland and barriers to their usage. Irish Journal of Medical Science (1971 -).
Crossref
Reena Nair, Gull Mohammad Bhat, Narendra Agrawal, Manju Sengar, Pankaj Malhotra, Soniya Nityanand, Chitra Lele, Pramod Reddy, Suresh Kankanwadi & Narendra Maharaj. (2023) Real-world outcomes of diffuse large B-cell lymphoma in the biosimilar era. Frontiers in Oncology 13.
Crossref
Beate Bittner. (2023) Customer-centric product presentations for monoclonal antibodies. AAPS Open 9:1.
Crossref
Qiyou Wu, Zhiwei Lian, Xin Wang, Hanchao Cheng, Jing Sun, Hui Yu, Gong Zhang, Fan Wu, Jian Liu & Chuanben Chen. (2023) Factors associated with the uptake of biosimilars for breast cancer treatment from the perspectives of physicians and patients-Evidence from China. Frontiers in Pharmacology 13.
Crossref
Jia-Wei Liu, Yu-Huan Yang, Nan Wu & Ji-Fu Wei. (2022) Biosimilar monoclonal antibodies in China: A patent review. Bioengineered 13:6, pages 14503-14518.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.